Related Experiment Video
Updated: Jul 18, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Sympatholytic therapy in primary hypertension: a user friendly role for the future
1Keck School of Medicine, University of Southern California, LA, California, USA.
Journal of Human Hypertension
|May 3, 2002
Summary
For 50 years, hypertension therapy has targeted the sympathetic nervous system (SNS). While older drugs had side effects, beta-blockers remain key, with future treatments focusing on specific SNS pathways.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Neuroscience
Background:
- Hypertension therapy has evolved over 50 years, with a historical focus on the sympathetic nervous system (SNS).
- Early therapies like ganglionic blockers and reserpine targeted noradrenaline (NA) but caused significant side effects.
- Later agents like clonidine and methyldopa offered alternative mechanisms within SNS modulation.
Purpose of the Study:
- To review the historical development and mechanisms of action of therapies targeting the sympathetic nervous system in primary hypertension.
- To evaluate the efficacy and limitations of various antihypertensive drug classes.
- To explore future directions in hypertension management focusing on novel SNS-targeted agents.
Main Methods:
- Historical review of antihypertensive pharmacotherapy.
- Analysis of drug mechanisms targeting sympathetic nervous system pathways.
- Evaluation of clinical outcomes and side effect profiles associated with different drug classes.
Main Results:
- Early SNS inhibitors (reserpine, guanethidine) depleted noradrenaline but caused adverse effects like depression and postural hypotension.
- Clonidine and methyldopa act centrally and peripherally on adrenergic and imidazoline receptors, with associated side effects.
- Alpha-receptor antagonists show increased risk of heart failure, while beta-receptor antagonists remain crucial due to mortality benefits in specific cardiovascular conditions.
Conclusions:
- The sympathetic nervous system plays a critical role in hypertension pathogenesis and treatment.
- Beta-blockers are a cornerstone therapy, particularly in patients with systolic dysfunction or post-myocardial infarction.
- Future research focuses on developing targeted SNS therapies, including specific imidazoline agents and angiotensin receptor blockers with presynaptic affinity.
Related Concept Videos
01:16Antihypertensive Drugs: Action of Diuretics
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...